Peringatan Keamanan

Symptoms of overdose include thrombocytopenia.

Ethchlorvynol

DB00189

small molecule approved illicit withdrawn

Deskripsi

Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

Struktur Molekul 2D

Berat 144.6
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly absorbed from gastrointestinal tract.

Metabolisme

About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol.
  • 2. Take with food. Food reduces irritation.

Interaksi Obat

665 Data
Buprenorphine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Hydrocodone Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Magnesium sulfate The therapeutic efficacy of Ethchlorvynol can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Ethchlorvynol may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Mirtazapine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Orphenadrine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Pramipexole Ethchlorvynol may increase the sedative activities of Pramipexole.
Ropinirole Ethchlorvynol may increase the sedative activities of Ropinirole.
Rotigotine Ethchlorvynol may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethchlorvynol.
Suvorexant Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Thalidomide Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ethchlorvynol.
Sodium oxybate Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Ethanol Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Fluvoxamine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Cyproheptadine.
Imipramine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Imipramine.
Nortriptyline The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Nortriptyline.
Amoxapine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Amoxapine.
Propiomazine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Propiomazine.
Maprotiline The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Maprotiline.
Doxepin The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Doxepin.
Desipramine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Desipramine.
Pizotifen The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Ethchlorvynol.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Ethchlorvynol.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Ethchlorvynol.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Ethchlorvynol.
Succinylcholine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Succinylcholine.
Reserpine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Reserpine.
Eletriptan The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Eletriptan.
Enflurane The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Enflurane.
Temazepam The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Temazepam.
Reboxetine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Reboxetine.
Butabarbital The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Butabarbital.
Butalbital The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Butalbital.
Methysergide The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Methysergide.
Cabergoline The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Cabergoline.
Phenytoin The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Phenytoin.
Topiramate The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Topiramate.
Clemastine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Clemastine.
Venlafaxine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Venlafaxine.
Etomidate The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Etomidate.
Morphine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Morphine.
Talbutal The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Talbutal.
Pentobarbital The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Pentobarbital.
Valproic acid The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Valproic acid.
Zolmitriptan The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Zolmitriptan.
Codeine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Codeine.
Dihydroergotamine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Dihydroergotamine.
Tolcapone The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Tolcapone.
Hydromorphone The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Hydromorphone.
Olanzapine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Olanzapine.
Cetirizine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Cetirizine.
Protriptyline The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Protriptyline.
Trimethadione The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Trimethadione.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Ethchlorvynol.
Chlorzoxazone The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Chlorzoxazone.
Clozapine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Clozapine.
Meprobamate The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Meprobamate.
Thiethylperazine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Thiethylperazine.
Palonosetron The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Palonosetron.
Sulpiride The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Sulpiride.
Alprazolam The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Alprazolam.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Dexbrompheniramine.
Loxapine The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Loxapine.
Remoxipride The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Remoxipride.

Target Protein

Gamma-aminobutyric acid receptor subunit beta-2 GABRB2
Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1
GABA(A) Receptor GABRA1

Referensi & Sumber

Synthesis reference: Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.

Contoh Produk & Brand

Produk: 3 • International brands: 5
Produk
  • Placidyl Cap 200mg
    Capsule • 200 mg • Oral • Canada • Approved
  • Placidyl Cap 500mg
    Capsule • 500 mg • Oral • Canada • Approved
  • Placidyl Cap 750mg
    Capsule • 750 mg • Oral • Canada • Approved
International Brands
  • Arvynol — Pfizer
  • Nostel — Dainippon
  • Placidyl — Abbott
  • Roeridorm — Pfizer-Roerig
  • Serenesil — Abbott

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul